Cardiac MRI techniques for clinical drug trials

In Vivo MR Techniques in Drug Discovery and Development

Volumn , Issue , 2006, Pages 329-350

  Kelle, Sebastian ^a   Nagel, Eike ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 50149110168     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Pennell, D. J. et al., Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report, Eur. Heart J., 25, 1940, 2004.
2. Nagel, E., Rossum, A. v., and Fleck, E., Cardiovascular Magnetic Resonance, Steinkopff, Darmstadt, 2004.
3. Sokolow, M., McIlroy, M. B., and Cheitlin, M. D., Clinical Cardiology, 5th ed., Lange Medical Publications, 1990.
4. Kazzam, E. et al., Hypertension-still an important cause of heart failure?, J. Hum. Hypertens., 19, 267, 2005.
5. Dahlström, U., Frequent non-cardiac comorbidities in patients with chronic heart failure, Eur. J. Heart Fail., 7, 309, 2005.
6. Kaplan, N. M., Systemic hypertension: mechanisms and diagnosis, In Braunwald-Heart Disease, Braunwald, E., Ed., WB Saunders Co, Philadelphia, PA, pp. 817-851, 1992.
7. Braunwald, E., Valvular heart disease, In Braunwald-Heart Disease, Braunwald, E., Ed., WB Saunders Co, Philadelphia, PA, pp. 1007-1077, 1992.
8. Wilson, P. W., An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure, Am. J. Cardiol., 80, 3J, 1997.
9. Otto, C. M. et al., Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly, N. Engl. J. Med., 341, 142, 1999.
10. Stewart, B. F. et al., Clinical factors associated with calcific aortic valve disease, J. Am. Coll. Cardiol., 29, 630, 1997.
11. Gould, K., Kirkeeide, R., and Buchi, M., Coronary flow reserve as a physiologic measure of stenosis severity, J. Am. Coll. Cardiol., 15, 459, 1990.
12. Mahrholdt, H., Wagner, A., and Sechtem, U., Congenital heart disease and cardiomyopathies, In Cardiovascular Magnetic Resonance, Nagel, E., van Rossum, A. C., and Fleck, E., Eds., Steinkopf, Darmstadt, pp. 105-132, 2004.
13. Wynne, J. and Braunwald, E., The cardiomyopathies and myocarditis: toxic, chemical, and physical damage to the heart, In Braunwald-Heart Disease, Braunwald, E., Ed., WB Saunders Co, Philadelphia, PA, pp. 1394-1450, 1992.
14. Maceira, A. M. et al., Cardiovascular magnetic resonance in cardiac amyloidosis, Circulation, 111, 186, 2005.
15. Vignaux, O., Cardiac sarcoidosis: spectrum of MRI features, Am. J. Roentgenol., 184, 249, 2005.
16. Kuntz, K. M. et al., Cost-effectiveness of diagnostic strategies for patients with chest pain, Ann. Intern. Med., 130, 709, 1999.
17. Ndrepepa, G. et al., Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction, Am. J. Cardiol., 95, 553, 2005.
18. Arroyo-Espliguero, R. et al., C-reactive protein elevation and disease activity in patients with coronary artery disease, Eur. Heart J., 25, 401, 2004.
19. Johnson, B. D. et al., Serum Amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation (WISE), Circulation, 109, 726, 2004.
20. Clejan, S. et al., Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis, J. Cell. Mol. Med., 6, 583, 2002.
21. Kragelund, C. et al., N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease, N. Engl. J. Med., 352, 666, 2005.
22. Thiele, H. et al., Functional cardiac MR imaging with steady-state free precession (SSFP) significantly improves endocardial border delineation without contrast agents, J. Magn. Reson. Imaging, 14, 362, 2001.
23. Thiele, H. et al., Improved accuracy of quantitative assessment of left ventricular volume and ejection fraction by geometric models with steady-state free precession, J. Cardiovasc. Magn. Reson., 4, 327, 2002.
24. Bellenger, N. et al., Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance, J. Cardiovasc. Magn. Reson., 2, 271, 2000.
25. Otterstad, J. E. et al., Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function, Eur. Heart J., 18, 507, 1997.
26. Kaus, M. R. et al., Automated segmentation of the left ventricle in cardiac MRI, Med. Image Anal., 8, 245, 2004.
27. Nagel, E. et al., Stress cardiovascular magnetic resonance: consensus panel report, J. Cardiovasc. Magn. Reson., 3, 267, 2001.
28. Nagel, E. et al., Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography, Circulation, 99, 763, 1999.
29. Wahl, A. et al., High-dose dobutamine-atropine stress cardiovascular MR imaging after coronary revascularization in patients with wall motion abnormalities at rest, Radiology, 233, 210, 2004.
30. Nagel, E. et al., Influence of image quality on the diagnostic accuracy of dobutamine stress magnetic resonance imaging in comparison with dobutamine stress echocardiography for the noninvasive detection of myocardial ischemia, Z. Kardiol., 88, 622, 1999.
31. Wahl, A. et al., Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases, Eur. Heart. J., 25, 1230, 2004.
32. Hundley, W. G. et al., Magnetic resonance imaging determination of cardiac prognosis, Circulation, 106, 2328, 2002.
33. Castillo, E., Lima, J. A. C., and Bluemke, D. A., Regional myocardial function: advances in MR imaging and analysis, Radiographics, 23, 127S, 2003.
34. Garot, J. et al., Fast determination of regional myocardial strain fields from tagged cardiac images using harmonic phase MRI, Circulation, 101, 981, 2000.
35. Osman, N. F. et al., Cardiac motion tracking using CINE harmonic phase (HARP) magnetic resonance imaging, Magn. Reson. Med., 42, 1048, 1999.
36. Azevedo, C. F. et al., Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging, Eur. Heart J., 25, 1419, 2004.
37. Al-Saadi, N. et al., Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance, Circulation, 101, 1379, 2000.
38. Al-Saadi, N. et al., Improvement of myocardial perfusion reserve early after coronary intervention: assessment with cardiac magnetic resonance imaging, J. Am. Coll. Cardiol., 36, 1557, 2000.
39. Schwitter, J. et al., Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography, Circulation, 103, 2230, 2001.
40. Paetsch, I. et al., Cardiac magnetic resonance (CMR) imaging: a noninvasive tool for functional and morphological assessment of coronary artery disease: current clinical applications and potential future concepts, J. Interv. Cardiol., 16, 457, 2003.
41. Wagner, A. et al., Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study, Lancet, 361, 374, 2003.
42. Panting, J. R. et al., Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging, N. Engl. J. Med., 346, 1948, 2002.
43. Giang, T. H. et al., Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience, Eur. Heart J., 25, 1657, 2004.
44. Wolff, S. D. et al., Myocardial first-pass perfusion magnetic resonance imaging: a multicenter doseranging study, Circulation, 110, 732, 2004.
45. Kelle, S. et al., Potential intrinsic error of noninvasive coronary angiography, J. Cardiovasc. Magn. Reson., 7, 1, 2005.
46. Jahnke, C. et al., Coronary MR angiography with steady-state free precession: individually adapted breath-hold technique versus free-breathing technique, Radiology, 232, 669, 2004.
47. Kim, W. Y. et al., Coronary magnetic resonance angiography for the detection of coronary stenoses, N. Engl. J. Med., 345, 1863, 2001.
48. Jaffer, F. A. et al., Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study, Arterioscler. Thromb. Vasc. Biol., 22, 849, 2002.
49. Helft, G. et al., Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging, Circulation, 105, 993, 2002.
50. Li, A. E. et al., Using MRI to assess aortic wall thickness in the multiethnic study of atherosclerosis: distribution by race, sex, and age, Am. J. Roentgenol., 182, 593, 2004.
51. Fayad, Z. A. et al., In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography, Circulation, 101, 2503, 2000.
52. Barkhausen, J. et al., Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging, Circulation, 108, 605, 2003.
53. Botnar, R. M. et al., In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent, Circulation, 110, 1463, 2004.
54. Winter, P. M. et al., Molecular imaging of angiogenesis in early-stage atherosclerosis with (alpha)v(beta)3-integrin-targeted nanoparticles, Circulation, 108, 2270, 2003.
55. Judd, R. M. et al., Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts, Circulation, 92, 1902, 1995.
56. Kim, R. J. et al., Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function, Circulation, 100, 1992, 1999.
57. Klein, C. et al., Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography, Circulation, 105, 162, 2002.
58. Kim, R. J. et al., The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction, N. Engl. J. Med., 343, 1445, 2000.
59. Choi, K. M. et al., Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function, Circulation, 104, 1101, 2001.
60. Wellnhofer, E. et al., Magnetic resonance low-dose dobutamine test is superior to scar quantification for the prediction of functional recovery, Circulation, 109, 2172, 2004.
61. McCrohon, J. A. et al., Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance, Circulation, 108, 54, 2003.
62. Moon, J. C. et al., Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance, J. Am. Coll. Cardiol., 41, 1561, 2003.
63. Choudhury, L. et al., Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 40, 2156, 2002.
64. Friedrich, M. G. et al., Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis, Circulation, 97, 1802, 1998.
65. Glagov, S. et al., Compensatory enlargement of human atherosclerotic coronary arteries, N. Engl. J. Med., 316, 1371, 1987.
66. Bellenger, N. G. et al., Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study, Heart, 90, 760, 2004.
67. Corti, R. et al., Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging, Circulation, 106, 2884, 2002.
68. Fayad, Z. A. and Fuster, V., Clinical imaging of the high-risk or vulnerable atherosclerotic plaque, Circ. Res., 89, 305, 2001.
69. Weissleder, R. and Ntziachristos, V., Shedding light onto live molecular targets, Nat. Med., 9, 123, 2003.
70. Grothues, F. et al., Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy, Am. J. Cardiol., 90, 29, 2002.
71. Bellenger, N. G. et al., Quantification of right and left ventricular function by cardiovascular magnetic resonance, Herz, 25, 392, 2000.
72. Bellenger, N. G. et al., Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance, J. Cardiovasc. Magn. Reson., 2, 271, 2000.
73. Mahrholdt, H. et al., Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging, Circulation, 106, 2322, 2002.
74. 2 measurements of tissue iron in thalassemia, J. Magn. Reson. Imaging, 18, 616, 2003.
75. Grothues, F. et al., Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance, Am. Heart J., 147, 218, 2004.
76. Bates, J. H. and Irvin, C. G., Measuring lung function in mice: The phenotyping uncertainty principle, J. Appl. Physiol., 94, 1297, 2003.
77. Abboud, R. T., Ford, G. T., and Chapman, K. R., Emphysema in alpha1-antitrypsin deficiency: Does replacement therapy affect outcome?, Treat. Respir. Med., 4, 1, 2005.
78. Berger, P. et al., Airway wall thickness in cigarette smokers: Quantitative thin-section CT assessment, Radiology, 235, 1055, 2005.
79. Robinson, T. E. et al., Domase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis, Chest, 128, 2327, 2005.
80. Lam, S. et al., A randomized phase IIb trial of Pulmicort Turbuhaler (Budesonide) in people with Dysplasia of the bronchial epithelium, Clin. Cancer Res., 10, 6502, 2004.
81. Robinson, T. E. et al., Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease, Am. J. Respir. Crit. Care Med., 168, 588, 2003.